NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Narendra Modi
    Amit Shah
    Box Office Collection
    Bharatiya Janata Party (BJP)
    OTT releases
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout


    India Business World Politics Sports Technology Entertainment Auto Lifestyle Inspirational Career Bengaluru Delhi Mumbai Visual Stories Find Cricket Statistics Phones Reviews Fitness Bands Reviews Speakers Reviews

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
     
    Home / News / India News / SII's Covishield, Bharat Biotech's COVAXIN granted emergency approval, says DCGI
    SII's Covishield, Bharat Biotech's COVAXIN granted emergency approval, says DCGI
    1/7
    India 3 min read

    SII's Covishield, Bharat Biotech's COVAXIN granted emergency approval, says DCGI

    By Siddhant Pandey
    Jan 03, 2021
    11:58 am
    SII's Covishield, Bharat Biotech's COVAXIN granted emergency approval, says DCGI

    Two COVID-19 vaccines, Covishield and COVAXIN, have been granted emergency approval for use in India, the Drugs Controller General of India (DCGI) Dr. VG Somani said on Sunday. Covishield has been developed by AstraZeneca and Oxford University, and manufactured by Pune-based Serum Institute of India (SII), while COVAXIN has been developed indigenously by the Hyderabad-based Bharat Biotech. Here are more details.

    2/7

    2 vaccines approved for 'restricted use in emergency situation'

    While addressing a press conference, Dr. Somani said, "After adequate examination, the CDCSO has decided to accept the recommendations of the expert committee, and accordingly, the vaccines of Serum Institute of India and Bharat Biotech are being approved for restricted use in an emergency situation." "Permission is being granted to Cadila Healthcare for the conduct of Phase III clinical trials in India," he added.

    3/7

    Earlier, concerns were raised about nod to vaccines

    Earlier on Saturday, the Subject Expert Committee (SEC) of the Central Drugs Standards Control Organisation (CDSCO) had recommended the grant of emergency approval to COVAXIN. A day earlier, the same panel had recommended emergency approval for Covishield. The nod to COVAXIN was deemed controversial as the recommendation came despite a lack of Phase III trial data indicating the vaccine's efficacy.

    4/7

    Covishield 95% effective if doses given 3 months apart: SII

    Both Covishield and COVAXIN are two-dose vaccines. SII CEO Adar Poonawalla had said last week that Covishield is "90-95% effective" if the two doses are given two-three months apart. Earlier, he had said that India has 40-50 million doses already stockpiled.

    5/7

    'Vaccines are 110% safe,' says DCGI

    Addressing criticism over vaccine approval, the DCGI told reporters, "We would never approve (a vaccine) if there are any safety concerns... The vaccines are 110% safe." "There are some mild side-effects, such as pain on the injection site, mild fever, and allergy. But these are common for every vaccine," he said, declaring the claims of impotency being a side-effect "absolute rubbish."

    6/7

    'Decisive turning point,' says PM Modi

    In a series of tweets, Prime Minister Narendra Modi said the development marked a "decisive turning point to strengthen a spirited fight." "Congratulations India. Congratulations to our hardworking scientists and innovators," he wrote. The PM further said that India will remain "eternally grateful" to the doctors, medical staff, scientists, police personnel, sanitation workers, and all "corona warriors" at the frontlines of the pandemic.

    7/7

    How bad is the outbreak in India?

    As of Sunday morning, India has reported 1,03,23,965 COVID-19 cases, with a spike of 18,177 new infections reported in the past 24 hours. The total cases include 2,47,220 active infections, while 99,27,310 people have recovered. The death toll has risen to 1,49,435 with 217 new fatalities over a 24-hour period. India is the world's second worst-hit country in the outbreak after the United States.

    Facebook
    Whatsapp
    Twitter
    Linkedin
    Related News
    Drugs Controller General of India
    Serum Institute of India
    Bharat Biotech
    COVAXIN

    Drugs Controller General of India

    Coronavirus vaccine: Bharat Biotech's COVAXIN gets expert panel nod Union Health Ministry
    India set to start COVID-19 vaccination; panel approves Oxford vaccine Oxford
    India could start 2021 with COVID-19 vaccine in hand: DCGI India
    Pfizer seeks emergency approval for COVID-19 vaccine in India Pfizer

    Serum Institute of India

    India could approve coronavirus vaccine soon, key meeting today Pfizer
    Coronavirus: 'Davai bhi, kadaai bhi,' Modi calls for sustained caution Narendra Modi
    Centre extends COVID-19 surveillance guidelines till January 31 India
    Oxford/AstraZeneca vaccine should be effective against new variant: Report Oxford University

    Bharat Biotech

    Coronavirus vaccination may start in January, says Health Minister NITI Aayog
    COVID-19 vaccine: India to produce 300 million Sputnik V doses India
    India's neighbors train experts for clinical trials of COVID-19 vaccine Sri Lanka
    How Delhi plans to carry out COVID-19 vaccinations All India Institute Of Medical Sciences (AIIMS)

    COVAXIN

    No emergency approval for SII, Bharat Biotech's vaccine candidates yet Serum Institute of India
    Now, Bharat Biotech seeks emergency use approval for COVAXIN Indian Council of Medical Research (ICMR)
    Haryana minister, who received dose of coronavirus vaccine, tests positive India
    Bharat Biotech vaccine trials continued despite 'adverse event' in August Indian Council of Medical Research (ICMR)
    Next News Article

    Love India News?

    Subscribe to stay updated.

    India Thumbnail
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2023